Doxorubicin, in concentrations that have no effect on fast or slow response action potentials, has been shown to suppress ouabain-induced delayed afterdepolarizations. In this study, we used standard microelectrode techniques to determine the effects of doxorubicin on isolated canine Purkinje fibers. We studied automaticity induced at normal and low membrane potentials, conduction in normal and K'-depolarized Purkinje fibers, and triggered activity induced by ouabain and by experimental myocardial infarction. Doxorubicin, 50 ,uM, suppressed the triggered activity and the delayed afterdepolarizations that induced it, but had no effect on the other variables. We then studied the effects of intravenous doxorubicin, 16 to 64 mg/m2 body surface area, on ouabain-induced ventricular tachycardia and the ventricular tachycardia that occurs 24 hr after ligation of the left anterior descending coronary artery in the intact dog. There was no effect on the infarct-induced arrhythmia, but concentrations of doxorubicin that had no other effect on the electrocardiogram suppressed those ouabain-induced arrhythmias that appeared to have been triggered. The automatic arrhythmias induced by ouabain were not affected. Both the latter mechanisms were verified in studies of isolated Purkinje fibers that were obtained on completion of the intact animal experiments. These results indicate that agents having high selectivity for specific arrhythmogenic mechanisms can be useful adjuncts in discriminating among the mechanisms responsible for arrhythmias in intact animals. Circulation 74, No. 4, 881-889, 1986. BECAUSE the characteristic responses to programmed electrical stimulation of such disparate mechanisms as reentry, triggered activity, and automaticity at low levels of membrane potential may at times be overlapping, the use of pacing alone to discriminate among them can be misleading (see references 1 to 4 for detailed discussion). For this reason, we5 and others6 have been using electrophysiologic testing and matrixes of drugs in an attempt to identify mechanism with a greater degree of accuracy in experimental animals and in patients. Although results with this approach have been promising, its use has been limited by the fact that most drugs act via more than one mechanism, thereby rendering discrimination among mechanisms difficult. Here we report results with the anthracycline antibiotic doxorubicin, which October 1986 has been shown in isolated tissue studies to predominantly modify one mechanism, delayed afterdepolarizations and resultant triggered activity.7 Although the doxorubicin dosages used clinically for cancer chemotherapy result in significant cardiac and noncardiac toxicity,8 we will demonstrate that the selectivity of this drug for a specific arrhythmogenic mechanism in isolated tissues and intact animals is such to encourage the search for other agents having comparably high selectivity and lesser toxicity.
Methods